The risk of developing myocarditis is seven times greater from being infected by COVID-19 than from getting the vaccine, according to a new study.
According to a recent study by Penn State College of Medicine scientists, the risk of developing myocarditis — or inflammation of the heart muscle — is seven times higher with a COVID-19 infection than with the COVID-19 vaccine. Patients with myocarditis suffer from varied symptoms depending on their current cardiovascular health, the severity of inflammation, and other factors. They often experience chest pains, shortness of breath, or an irregular heartbeat. In severe cases, myocarditis can lead to heart failure and death.
Myocarditis, also known as inflammatory cardiomyopathy, is inflammation of the heart muscle. It is caused by the body’s immune system in response to an infection or some other trigger, such as a vaccine, a reaction to medication, or exposure to heavy metals.
“Our findings show that the risk of myocarditis from being infected by COVID-19 is far greater than from getting the vaccine,” said Dr. Navya Voleti. “Moving forward, it will be important to monitor the potential long-term effects in those who develop myocarditis.” Voleti is a resident physician in the Department of Medicine at Penn State Health Milton S. Hershey Medical Center.
Myocarditis is one of the many complications of SARS-CoV-2 infection. (SARS-CoV-2 is the virus that causes COVID-19 disease.) Although it has been demonstrated that vaccines reduce severe COVID-19 symptoms, heart complications have been linked with mRNA COVID-19 vaccination — especially myocarditis in teenage boys. However, thus far, large studies had not characterized the relative risk of myocarditis due to vaccines and infections in detail.
Therefore, the Penn State team conducted the largest study to date on the risk of developing myocarditis as a result of having the coronavirus vs. experiencing inflammation following COVID-19 vaccination. The researchers compared patients with COVID-19 — vaccinated and unvaccinated — to those without the virus. They found the risk of myocarditis was 15 times higher in COVID-19 patients, regardless of vaccination status, compared to individuals who did not contract the virus.
Next, the researchers separately compared the rates of myocarditis in those who received the vaccines to those in unvaccinated individuals. According to the findings, the rates of myocarditis in people who were vaccinated against COVID-19 were only twofold higher than in unvaccinated people.
Based on all the findings, the investigators concluded that the risk of myocarditis due to COVID-19 was seven times higher than the risk related to the vaccines.
Scientists conducted a systematic review and meta-analysis of 22 studies published worldwide from December 2019 through May 2022. The studies included nearly 58 million patients who reported cardiac complications and belonged to one of two groups: the 55.5 million who were vaccinated against COVID-19 compared to those who were not vaccinated (vaccination group), and the 2.5 million who contracted the virus compared to those who did not contract the virus (COVID-19 group).
In the vaccination group, the research team separately compared the risk of myocarditis for various COVID-19 vaccines, including mRNA (Pfizer, Moderna), Novavax, AstraZeneca, and Johnson and Johnson. The median age of the study population was 49 years; 49% were men; and the median follow-up time after infection or COVID-19 vaccination was 28 days.
The investigators found that among those diagnosed with myocarditis after receiving the vaccine or having COVID-19, the majority (61%) were men. Of patients diagnosed with myocarditis in both vaccination and COVID-19 groups, 1.07% were hospitalized and 0.015% died.
“COVID-19 infection and the related vaccines both pose a risk for myocarditis. However, the relative risk of heart inflammation induced by COVID-19 infection is substantially greater than the risk posed by the vaccines,” said Dr. Paddy Ssentongo. He is the lead author of the study and a resident physician in the Department of Medicine at Penn State Health Milton S. Hershey Medical Center. “We hope our findings will help mitigate vaccine hesitancy and increase vaccine uptake.”
Reference: “Myocarditis in SARS-CoV-2 infection vs. COVID-19 vaccination: A systematic review and meta-analysis” by Navya Voleti, Surya Prakash Reddy and Paddy Ssentongo, 29 August 2022, Frontiers in Cardiovascular Medicine.
DOI: 10.3389/fcvm.2022.951314
Surya Reddy from Osmania Medical College also contributed to this research.
The researchers declare no conflicts of interest or specific funding for this research.
